Early, structured disease modifying anti-rheumatic drug (DMARD) therapy reduces cardiovascular risk in rheumatoid arthritis-a single centre study using non-biologic drugs

Journal of Association of Physicians of India

Volumn 61, Issue 8, 2013, Pages 11-14

  Chatterjee, Sumit ^a   Sarkate, Pankaj ^b   Ghosh, Sudip ^c   Biswas, Monodeep ^d   Ghosh, Alakendu ^e  

^a WBUHS   (India)

^b KEM HOSPITAL   (India)

^c MEDICAL COLLEGE AND HOSPITAL   (India)

^d University of Jefferson   (United States)

^e INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84881193472     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376:1094-108.
2. Biswas M, Chatterjee A, Ghosh SK et al. Prevalence, types, clinical associations and determinants of peripheral neuropathy in rheumatoid patients. Ann Indian Acad Neurol 2011;14:194-7.
3. Chopra A, Patil J, Billempelly V, Relwani J, Tandle HS. Prevalence of rheumatic diseases in a rural population in western India: a WHO-ILAR COPCORD Study. J Assoc Physicians India 2001;49:240-6.
4. Malaviya AN, Kapoor SK, Singh RR, Kumar A, Pande I. Prevalence of rheumatoid arthritis in the adult Indian population. Rheumatol Int 1993;13:131-4.
5. Aletaha D, Neogi T, Silman AJ, Funovits J et al. Rheumatoid Arthritis Classification Criteria. Arthritis Rheum 2010;62:2569-2581
6. Cush JJ. Early rheumatoid arthritis --is there a window of combination therapy with non-biological disease-modifying opportunity? J Rheumatol Suppl 2007;80:1-7.
7. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59:1690-7.
8. Kary S, Fritz J, Scherer HU, Burmester GR. Do we still miss the chance of effectively treating early rheumatoid arthritis? New answers from a new study. Rheumatology (Oxford) 2004;43:819-20.
9. Inanc M. Very early 'Rheumatoid' arthritis cohorts: limited by selection. Rheumatology (Oxford) 2007;46:185-7.
10. Bartoloni E, Alunno A, Bistoni O, Gerli R. How early is the atherosclerotic risk in rheumatoid arthritis? Autoimmun Rev 2010;9:701-7.
11. Badsha H, Kong KO, Tak PP. Rheumatoid arthritis in the United Arab Emirates. Clin Rheumatol 2008;27:739-42.
12. Edwards CJ, Syddall H, Goswami R et al. The autoantibody rheumatoid factor may be.an independent risk factor for ischaemic heart disease in men. Heart 2007;93:1263-7
13. Mäkinen H, Kautiainen H, Hannonen P. Disease activity score 28 as an instrument to measure disease activity in patients with early rheumatoid arthritis. J Rheumatol 2007;34:1987-91.
14. Rizzo M, Spinas GA, Cesur M, Ozbalkan Z, Rini GB, Berneis K. Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis. Atherosclerosis 2009;207:502-6.
15. Ghosh UC, Roy A, Sen K, Kundu AK, Saha I, Biswas A. Dyslipidaemia in rheumatoid arthritis in a tertiary care centre in Eastern India--a non-randomised trial. J Indian Med Assoc 2009;107:427-30.
16. Chatterjee Adhikari M, Guin A, Chakraborty S, Sinhamahapatra P, Ghosh A. Subclinical Atherosclerosis and Endothelial Dysfunction in Patients with Early Rheumatoid Arthritis as Evidenced by Measurement of Carotid Intima-Media Thickness and Flow-Mediated Vasodilatation: An Observational Study. Semin Arthritis Rheum 2011 Oct 27.
17. Tyrrell PN, Beyene J, Feldman BM, McCrindle BW, Silverman ED, Bradley TJ. Rheumatic disease and carotid intima-media thickness: a systematic review and meta-analysis. Arterioscler Thromb Vasc Biol 2010;30:1014-26.
18. Katchamart W, Trudeau J, Phumethum V, Bombardier C. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2009;68:1105-12.
19. Möttönen T, Hannonen P, Leirisalo-Repo M. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999;353:1568-73.
20. Feely MG, O'Dell JR. Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis. Curr Opin Rheumatol 2010;22:316-20.
21. Saag KG, Teng GG, Patkar NM et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84.
22. Saunders SA, Capell HA, Stirling A et al. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum 2008;58:1310-7.
23. Resman-Targoff BH, Cicero MP. Treatment of early rheumatoid arthritis: recognizing the window of opportunity and treating to target goals. Am J Manag Care 2010;16(9 Suppl):S249-58.
24. Georgiadis AN, Voulgari PV, Argyropoulou MI et al. Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. Semin Arthritis Rheum 2008;38:13-9
25. van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006;8:R1
26. Turiel M, Tomasoni L, Sitia S et al. Effects of long-term disease-modifying antirheumatic drugs on endothelial function in patients with early rheumatoid arthritis. Cardiovasc Ther 2010;28:e53-64.
27. Benucci M, Saviola G, Manfredi M, Sarzi-Puttini P, Atzeni F. Cost effectiveness analysis of disease-modifying antirheumatic drugs in rheumatoid arthritis. A systematic review literature. Int J Rheumatol 2011;84:54-96.
28. Doan QV, Chiou CF, Dubois RW. Review of Eight Pharmacoeconomic studies of the Biologic DMARDs in the management of Rheumatoid Arthritis. Journal of Managed Care Pharmacy 2006;12:555-69
29. Yen JH. Treatment of early rheumatoid arthritis in developing countries. Biologics or disease-modifying anti-rheumatic drugs? Biomed Pharmacother 2006;60:688-92.